Permanently oriented antibody immobilization for digoxin determination with a flow-through fluoroimmunosensor

Fernández, P; Durand, J. S.; Pérez-Conde, C; Paniagua, G
April 2003
Analytical & Bioanalytical Chemistry;Apr2003, Vol. 375 Issue 8, p1020
Academic Journal
This paper reports a new flow-through fluoroimmunosensor, the function of which is based on antibodies immobilized on an inmunoreactor of controlled-pore glass (CPG), for determination of digoxin, used in the treatment of congestive heart failure and artery disease. The immunosensor has a detection limit of 1.20 μg L-1 and provides high reproducibility (RSD=4.5% for a concentration of 0.0025 mg L-1, and RSD=6.7% for 0.01 mg L-1). The optimum working concentration range was found to be 1.2×10-3–4.0×10-2 mg L-1. The lifetime of the immunosensor was about 50 immunoassays; if stored unused its lifetime can be extended to three months. A sample speed of about 10–12 samples per hour can be attained. Possible interference from substances with structures similar to digoxin (morphine, heroin, tebaine, codeine, pentazocine and narcotine) was investigated. No cross-reactivity was seen at the highest digoxin: interferent ratio studied (1:100). The proposed fluoroimmunosensor was successfully used to determine digoxin concentrations in human serum samples.


Related Articles

  • Evaluation of Digoxin Dosing in Two Egyptian Hospitals A Pilot Study. Farid, Samar F.; Abbassia, Maggie M.; Sabrya, Nirmeen A.; Elkhaleq, Shaimaa Abd // Australian Journal of Basic & Applied Sciences;2009, Vol. 3 Issue 3, p1838 

    Introduction: Digoxin is one of the digitalis cardiac glycosides indicated in heart failure and atrial fibrillation. Due to individual variability in digoxin pharmacokinetics, digoxin doses need to be calculated based on patient's weight, renal function and indication. Furthermore, therapeutic...

  • Digibind.  // Royal Society of Medicine: Medicines;2002, p202 

    This article presents information on digibind, a proprietary, prescription-only preparation of digoxin-specific antibody fragment which can be used as an antidote to overdosage by the cardiac glycoside drugs digoxin and digitoxin. This drug is administered for emergency use by injection.

  • digoxin-specific antibody fragment.  // Royal Society of Medicine: Medicines;2002, p203 

    This article presents information on digoxin-specific antibody fragment which comprises antibody fragments that react with the glycosides, and can be used as an antidote to overdosage by the cardiac glycoside drugs digoxin and digitoxin. It is administered for emergency use by injection.

  • Digoxin.  // Reactions Weekly;2/14/2009, Issue 1239, p13 

    The article describes the case of an 81-year-old man who developed symptoms of digoxin toxicity after starting digoxicin therapy after an episode of atrial fibrillation. The man has experienced fatigue, malaise, loss of appetite and unintentional weight loss. Digoxin was stopped and he was...

  • Digoxin overdose.  // Reactions Weekly;7/23/2005, Issue 1061, p8 

    Presents a case study of elevated serum digoxin concentrations in a 76-year-old woman. Development of digoxin intoxication following an acute dioxin overdose; Findings from laboratory investigations; Measurement of the patient's serum digoxin concentration by different digoxin immunoassays.

  • Lanoxin. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p457 

    A definition of the term "Lanoxin" is presented. It refers to a brand name of digoxin, a digitalis drug.

  • Digoxin interaction.  // Reactions Weekly;11/24/2007, Issue 1179, p14 

    The article describes the case of a 76-year-old man who developed bradycardia, tiredness, oedema and an elevated digoxin concentration after receiving digoxin together with itraconzole. The symptoms were resolved and his digoxin concentration returned to therapeutic levels after itraconazole was...

  • Phase-Invariant Signature Algorithm. Prasad, Kailash; Gupta, Madan M. // Angiology;Nov1979, Vol. 30 Issue 11, p721 

    Focuses on a noninvasive technique for early detection and quantification of Ouabain-induced cardiac disorders. Usage of the treatment; Methodology; Data acquisition and processing.

  • Role of Carvedilol and Digoxin in Heart Failure. Miller, Karl E. // American Family Physician;7/15/2004, Vol. 70 Issue 2, p386 

    Discusses research being done on the use of digoxin, carvedilol or their combination in the treatment of patients with heart failure and persistent atrial fibrillation. Reference to a study by A.U. Khand et al, published in the December 3, 2003 issue of the "Journal of the American College of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics